Arch Biopartners Long Term Debt 2021-2024 | ACHFF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Arch Biopartners long term debt from 2021 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Arch Biopartners long term debt from 2021 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$78.6B
Takeda Pharmaceutical (TAK)	$44.1B
Merck (MKKGY)	$21.2B
Astellas Pharma (ALPMY)	$20.4B
Sandoz Group AG (SDZNY)	$19.7B
United Therapeutics (UTHR)	$18B
Summit Therapeutics (SMMT)	$15.6B
Neurocrine Biosciences (NBIX)	$12.6B
Shionogi (SGIOY)	$12.5B
Catalent (CTLT)	$10.9B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Jazz Pharmaceuticals (JAZZ)	$7.4B
Orion OYJ (ORINY)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.1B
Corcept Therapeutics (CORT)	$5.7B
Crinetics Pharmaceuticals (CRNX)	$4.8B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$2.9B
Catalyst Pharmaceuticals (CPRX)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
Soleno Therapeutics (SLNO)	$2.5B
NewAmsterdam Pharma (NAMS)	$2B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
Harrow (HROW)	$1.8B
Ocular Therapeutix (OCUL)	$1.7B
Xencor (XNCR)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
ARS Pharmaceuticals (SPRY)	$1.6B